Compare ZTO & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZTO | VANI |
|---|---|---|
| Founded | 2002 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 81.2M |
| IPO Year | 2016 | 2014 |
| Metric | ZTO | VANI |
|---|---|---|
| Price | $20.97 | $1.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $21.90 | $4.00 |
| AVG Volume (30 Days) | ★ 1.6M | 173.2K |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $6,673,175,085.00 | N/A |
| Revenue This Year | $12.15 | N/A |
| Revenue Next Year | $11.36 | N/A |
| P/E Ratio | $18.48 | ★ N/A |
| Revenue Growth | ★ 13.17 | N/A |
| 52 Week Low | $16.34 | $0.91 |
| 52 Week High | $22.01 | $1.92 |
| Indicator | ZTO | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 59.42 | 45.64 |
| Support Level | $20.71 | $1.25 |
| Resistance Level | $21.68 | $1.55 |
| Average True Range (ATR) | 0.37 | 0.07 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 56.90 | 40.07 |
ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 19.4% in 2024. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and its major shareholder with 78% voting rights as of March 31, 2025. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around an 8.9% interest.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.